PT  - JOURNAL ARTICLE
AU  - Afrose, Sharmin
AU  - Song, Wenjia
AU  - Nemeroff, Charles B.
AU  - Lu, Chang
AU  - Yao, Danfeng (Daphne)
TI  - Subpopulation-specific Machine Learning Prognosis for Underrepresented Patients with Double Prioritized Bias Correction
AID  - 10.1101/2021.03.26.21254401
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.03.26.21254401
4099  - http://medrxiv.org/content/early/2022/05/09/2021.03.26.21254401.short
4100  - http://medrxiv.org/content/early/2022/05/09/2021.03.26.21254401.full
AB  - Many clinical datasets are intrinsically imbalanced, dominated by overwhelming majority groups. Off-the-shelf machine learning models that optimize the prognosis of majority patient types (e.g., healthy class) may cause substantial errors on the minority prediction class (e.g., disease class) and demographic subgroups (e.g., Black or young patients). For example, our work found that missed death cases are 3.14 times higher than missed survival cases in a mortality prediction model. In the typical one-machine-learning-model-fits-all paradigm, racial and age disparities are likely to exist, but unreported. What makes it worse is the deceptive nature of widely used whole-population metrics, such as AUC-ROC. We show that some metrics fail to reflect serious prediction deficiencies. To mitigate representational biases, we design a double prioritized (DP) bias correction technique. Our method trains customized models for specific ethnicity or age groups, a substantial departure from the one-model-predicts-all convention. We report our findings on four prognosis tasks over two imbalanced clinical datasets. DP reduces relative disparities among race and age groups, 5.6% to 86.8% better than the 8 existing sampling solutions being compared, in terms of the minority class’ recall.Competing Interest StatementCBN declares consulting for the following companies in the last 12 months: ANeuroTech (a division of Anima BV), Taisho Pharmaceutical, Inc., Takeda, Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, Corcept Therapeutics Pharmaceuticals Company. CBN owns stock in Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness. CBN serves on the scientific advisory boards of ANeuroTech (a division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS. CBN is the board of directors of Gratitude America, ADAA, Xhale Smart, Inc. CBN has patents in antipsychotic drug delivery. All other authors do not have competing interests.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We submitted applications/forms to access the MIMIC III dataset from PhysioNet Team in MIT Laboratory for Computational Physiology and the SEER dataset from National Cancer Institute. We were granted to use the MIMIC III and SEER datasets after going through the registration procedures.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe MIMIC III and SEER data used in this study are not publicly downloadable but can be requested at their original sites. Parties interested in data access should visit the MIMIC III website (https://mimic.physionet.org/gettingstarted/access/) and the SEER website (https://seer.cancer.gov/data/access.html) to submit access requests. https://mimic.physionet.org/gettingstarted/access/ https://seer.cancer.gov/data/access.html